Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHEN26 in mild to moderate COVID-19
NCT05908071Phase 3Unknown
- Sponsor
- Kexing Biopharm
- Start
- May 2023
- Primary completion
- May 2024
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of obeldesivir in coronavirus disease 2019 (COVID-19), sponsored by Kexing Biopharm. Status: unknown.
02
Drugs
obeldesivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05908071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05908071.